NO980016L - Macrolides - Google Patents
MacrolidesInfo
- Publication number
- NO980016L NO980016L NO980016A NO980016A NO980016L NO 980016 L NO980016 L NO 980016L NO 980016 A NO980016 A NO 980016A NO 980016 A NO980016 A NO 980016A NO 980016 L NO980016 L NO 980016L
- Authority
- NO
- Norway
- Prior art keywords
- positions
- acid residue
- macrocyclic ring
- macrolides
- iii
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En ny klasse av makrolider, der i) posisjonene 2 til og med 6 av den makrocykliske ringen blir tilveiebragt med en pipe- ridazinylkarboksylsyrerest; og/eller ii) posisjonene 7 til og med 9 av den makrocykliske ringen blir tilveiebragt med en aro- matisk a-aminosyrerest; og/eller iii) posisjonene 10 til og med 12 av den makrocykliske ringen blir tilveiebragt med en alifatisk a-aminosyrerest, omfatter fortrinnsvis to, eller særlig alle tre av de karakteristiske strukturtrekkene i), ii) og iii), mer spesifikt en forbindelse med formel IXA new class of macrolides, wherein i) positions 2 through 6 of the macrocyclic ring are provided with a piperidazinylcarboxylic acid residue; and / or ii) positions 7 through 9 of the macrocyclic ring are provided with an aromatic α-amino acid residue; and / or iii) positions 10 through 12 of the macrocyclic ring are provided with an aliphatic α-amino acid residue, preferably comprising two, or more particularly all three of the characteristic structural features i), ii) and iii), more specifically a compound having formula IX
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9513596.8A GB9513596D0 (en) | 1995-07-04 | 1995-07-04 | Organic compounds |
GBGB9515495.1A GB9515495D0 (en) | 1995-07-28 | 1995-07-28 | Organic compounds |
PCT/EP1996/002952 WO1997002285A1 (en) | 1995-07-04 | 1996-07-04 | Macrolides |
Publications (2)
Publication Number | Publication Date |
---|---|
NO980016D0 NO980016D0 (en) | 1998-01-02 |
NO980016L true NO980016L (en) | 1998-03-02 |
Family
ID=26307320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO980016A NO980016L (en) | 1995-07-04 | 1998-01-02 | Macrolides |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0836616A1 (en) |
JP (1) | JPH11509092A (en) |
KR (1) | KR19990028724A (en) |
CN (1) | CN1193979A (en) |
AR (1) | AR006514A1 (en) |
AU (1) | AU708004B2 (en) |
BR (1) | BR9609324A (en) |
CA (1) | CA2224715A1 (en) |
CO (1) | CO4750713A1 (en) |
CZ (1) | CZ424297A3 (en) |
HU (1) | HUP9802320A3 (en) |
IL (1) | IL122844A0 (en) |
NO (1) | NO980016L (en) |
PL (1) | PL324346A1 (en) |
SK (1) | SK498A3 (en) |
TR (1) | TR199800001T1 (en) |
WO (1) | WO1997002285A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6124453A (en) * | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
GB9811854D0 (en) * | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
US7368423B1 (en) * | 2001-12-05 | 2008-05-06 | The Scripps Research Institute | Composition and method for treating chronic allograft rejection |
US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
BRPI0613142A2 (en) | 2005-06-17 | 2010-12-21 | Novartis Ag | use of sangliferin in hcv |
US8067024B2 (en) | 2006-02-10 | 2011-11-29 | Medtronic Vascular, Inc. | Medical devices to prevent or inhibit restenosis |
CN101289440B (en) * | 2007-06-29 | 2010-08-25 | 中国热带农业科学院热带生物技术研究所 | Polyene macrocyclic compounds, preparation thereof and applications |
US8962329B2 (en) | 2008-09-24 | 2015-02-24 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Gene cluster |
WO2011098805A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
BR112012019866A8 (en) | 2010-02-09 | 2017-12-26 | Biotica Tech Limited | COMPOUND, USE THEREOF, PHARMACEUTICAL COMPOSITION, AND PROCESS FOR PREPARING A COMPOUND |
WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
GB201008123D0 (en) | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
UY33775A (en) | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | MACROCYCLIC INHIBITORS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND THEIR USES |
MX348758B (en) * | 2010-12-20 | 2017-06-28 | Neurovive Pharmaceutical Ab | Sanglifehrin derivatives and methods for their production. |
JO3063B1 (en) | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | Innovative compound and methods for its production |
GB201118334D0 (en) | 2011-10-24 | 2011-12-07 | Biotica Tech Ltd | Novel dosage form |
US9090653B2 (en) | 2012-06-08 | 2015-07-28 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
AR091279A1 (en) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE |
BR112014030630A2 (en) | 2012-06-08 | 2017-06-27 | Gilead Sciences Inc | macrocyclic flaviviridae virus inhibitors |
US10857150B2 (en) | 2016-11-18 | 2020-12-08 | Abliva Ab | Use of sanglifehrin macrocyclic analogues as anticancer compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9318144D0 (en) * | 1993-09-01 | 1993-10-20 | Sandoz Ltd | Organic compounds |
WO1995015328A1 (en) * | 1993-11-30 | 1995-06-08 | Abbott Laboratories | Macrocyclic immunomodulators with novel cyclohexyl ring replacements |
-
1996
- 1996-07-03 AR ARP960103427A patent/AR006514A1/en unknown
- 1996-07-04 HU HU9802320A patent/HUP9802320A3/en unknown
- 1996-07-04 KR KR1019980700022A patent/KR19990028724A/en not_active Application Discontinuation
- 1996-07-04 EP EP96924886A patent/EP0836616A1/en not_active Withdrawn
- 1996-07-04 CZ CZ974242A patent/CZ424297A3/en unknown
- 1996-07-04 JP JP9504832A patent/JPH11509092A/en active Pending
- 1996-07-04 CN CN96196487A patent/CN1193979A/en active Pending
- 1996-07-04 BR BR9609324A patent/BR9609324A/en not_active Application Discontinuation
- 1996-07-04 SK SK4-98A patent/SK498A3/en unknown
- 1996-07-04 PL PL96324346A patent/PL324346A1/en unknown
- 1996-07-04 IL IL12284496A patent/IL122844A0/en unknown
- 1996-07-04 AU AU65193/96A patent/AU708004B2/en not_active Ceased
- 1996-07-04 TR TR1998/00001T patent/TR199800001T1/en unknown
- 1996-07-04 CA CA002224715A patent/CA2224715A1/en not_active Abandoned
- 1996-07-04 WO PCT/EP1996/002952 patent/WO1997002285A1/en not_active Application Discontinuation
- 1996-07-04 CO CO96034982A patent/CO4750713A1/en unknown
-
1998
- 1998-01-02 NO NO980016A patent/NO980016L/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR9609324A (en) | 1999-05-25 |
CZ424297A3 (en) | 1998-04-15 |
AU708004B2 (en) | 1999-07-29 |
HUP9802320A2 (en) | 1999-02-01 |
JPH11509092A (en) | 1999-08-17 |
MX9800217A (en) | 1998-07-31 |
EP0836616A1 (en) | 1998-04-22 |
CA2224715A1 (en) | 1997-01-23 |
CO4750713A1 (en) | 1999-03-31 |
WO1997002285A1 (en) | 1997-01-23 |
NO980016D0 (en) | 1998-01-02 |
AR006514A1 (en) | 1999-09-08 |
SK498A3 (en) | 1998-07-08 |
CN1193979A (en) | 1998-09-23 |
IL122844A0 (en) | 1998-08-16 |
AU6519396A (en) | 1997-02-05 |
PL324346A1 (en) | 1998-05-25 |
TR199800001T1 (en) | 1998-04-21 |
HUP9802320A3 (en) | 1999-03-29 |
KR19990028724A (en) | 1999-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO980016L (en) | Macrolides | |
CA2254408A1 (en) | Hair dye compositions containing 2,3 dialkyl-4-aminophenol and a 2-alkyl-1-naphthol | |
NO983487D0 (en) | Derivatives of camptothecin for use in the treatment of cancer | |
EP0251304A3 (en) | Glycosyl derivatives and use thereof | |
AU6954887A (en) | Oligopeptidyl nitrile derivatives, agents containing them, a process for their preparation, and their use | |
TW337977B (en) | Low VOC liquid formulations of 1, 2-benzisothiazolin-3-one and method of manufacture | |
CA2327679A1 (en) | Triphendioxazine dyestuffs for dyeing organic substrates | |
CA2247167A1 (en) | 2-hetaroylcyclohexane-1,3-diones | |
DK0518558T3 (en) | 1-methylcarbapenem derivatives, their preparation and their use as antibiotics | |
WO1999003817A3 (en) | Aliphatic propargylamines as cellular rescue agents | |
EP1550651A4 (en) | Glycerol derivative | |
CA2023089A1 (en) | Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia | |
CA2267945A1 (en) | Anticonvulsant derivatives useful in treating neuropathic pain | |
WO2001009122A3 (en) | Serotonergic benzofurans | |
ES2000908A6 (en) | Nematocidal agents. | |
CA2144344A1 (en) | Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents | |
BG104302A (en) | Method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids | |
ZA872664B (en) | Six-membered heterocyclic derivatives of n'-substituted-n,n'-diacylhydrazines | |
MX9500228A (en) | N-oxides of 4-arylpiperazines and 4-arylpiperdines. | |
CA2011642A1 (en) | Benzoxazine dyes | |
EA199900684A1 (en) | Iminoazanthracyclinone derivatives for the treatment of amyloidosis | |
DK0904270T3 (en) | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents | |
TW334337B (en) | Preparation and composition for a compound of controlling and preventing phytopathogenic fungi | |
CA2123101A1 (en) | Nitroxyalkylamide derivative | |
CA2236073A1 (en) | Intimal thickening inhibitory agent |